MeSH tree: C15.378.508.539
Researchers in the lab of Cancer Center at Illinois (CCIL) member Xing Wang have discovered the influential role of structural chirality, or "handedness," of a DNA nanostructure to dictate cancer cell response to targeted ...
Jun 8, 2026
0
6
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form ...
Jun 4, 2026
0
3
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office ...
Jun 3, 2026
0
4
With the publication of the long-term data from the RELAZA2 study, a research program developed over many years by Dresden University Medicine for the treatment of leukemia patients, has reached an important milestone. The ...
May 31, 2026
0
7
The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older ...
May 25, 2026
0
4
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that significantly improves treatment ...
May 21, 2026
0
5
Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body's ability to make new, healthy blood ...
May 12, 2026
0
15
For highly aggressive types of blood cancer, stem cell transplantation is often the only potentially curative therapy, yet even after a transplant, these cancers often return. Now a clinical trial, led by researchers at Washington ...
May 12, 2026
0
134
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are ...
May 7, 2026
0
13
Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased risk of hematologic SPMs, according to a review published online April 6 in Frontiers in Oncology.
Apr 30, 2026
0
5
